Conclusion: Our study demonstrates that CEA decrease serves as a surrogate for DpR in cet-based chemotherapy. The CEA response and DpR may be associated with clinical outcome of cet treatment regardless of tumor sidedness. Background: As the increased number of hemodialysis (HD) patients, opportunities of cancer chemotherapy for patients undergoing HD are increasing. However, there are no guidelines regarding the dosage and timing of cancer chemotherapy in HD patients due to a lack of evidence. Therefore, we conducted a pharmacokinetic study of 5-fulorouracil (5-FU) and oxaliplatin (L-OHP) in patients undergoing HD. Patients and Methods: The subjects were six HD patients who underwent FOLFOX therapy. We measured blood and dialysate concentrations of L-OHP, 5-FU, and 5-FU metabolites, including a-fluoro-b-alanine (FBAL), fluoroacetic acid, and ammonia for these patients. Results: The primary cancer sites were the small bowel and colorectum in one and five patients, respectively. Five patients underwent the modified FOLFOX6 regimen while one patient underwent the modified FOLFOX7 regimen. The timing of L-OHP administration was dialysis day in four patients and non-dialysis day in two patients. The blood concentrations of FBAL and fluoroacetic acid were elevated in all patient, while blood concentration 5-FU was within the target range in four patients. A second peak in the free platinum concentration between HD cycles was been observed for all patients, and the extent of the elevation varied depending on the residual renal function. The amount of L-OHP removal by dialysis was 10% or less of the administrated dose, and did not differ between patients who received L-OHP on the day of dialysis and those who received it on a non-dialysis day. Hyperammonemia, which is considered to be related to 5-FU administration, was observed in two patients, and conscious level deterioration was observed in one patient. Conclusion: Our study elucidated the pharmacokinetics of FOLFOX therapy in HD patients. These data may be useful for establishing the appropriate dosage and timing. Hyperammonemia should be monitored during FOLFOX therapy among HD patients. Background: Severe benign cicatricial stricture (SBCS) is a major complication after chemoradiotherapy (CRT) for esophageal carcinoma (EC), and causes oral intake impairment leading to deterioration of quality of life even after being cured. Aim of this study was to investigate risk factors of SBCS. Methods: The subjects of this study were patients with stage II/III (T3) EC who received CRT and achieved complete response (CR) between 2000 and 2011. SBCS was determined as disability of passage by diameter-9mm endoscope or procedure to treat symptoms of stricture at the time or after confirmation of CR. Results: Among 197 patients with Stage II/III (T3) treated by CRT, CR was obtained in 87 patients, who were included in this analysis. The median age was 63 years. Fifteen patients (17.2%) were female. The median follow-up time was 7.5 years. The cumulative incidence of SBCS was 15.2% (95%CI 8.5-23.7). Significant risk factors of SBCS were female (hazard ratio (HR) 3.2 (95%CI 1.0-9.7), p ¼ 0.04), requirement of soft/ liquid style diet (HR 5.6 (95%CI 1.7-17.9), p ¼ 0.004), tumor occupying 3/4 or grater of esophageal perimeter (HR 8.5 (95%CI 1.5-49.1), p ¼ 0.02) and disability of endoscope passage .2), p < 0.001) in univariate analysis. Hypoalbuminemia increased the risk of SBCS (HR 2.6 (95%CI 0.9-7.8), p ¼ 0.08) marginally. As for the factors during CRT, grade 2-4 esophagitis significantly increased the risk of SBCS (HR 5.6 (95%CI 1.4-23.1), p ¼ 0.02). Multivariate analysis showed that hypoalbuminemia 3), p ¼ 0.01) and disability of endoscope passage (HR 5.9 (95%CI 1.5-22.9), p ¼ 0.01) were the significant risk factors of SBCS. Conclusion: Obstructions and hypoalbuminemia before CRT and severe esophagitis during CRT are considered as risk factors of SBCS. Because SBCS occurred after
Background: Severe benign cicatricial stricture (SBCS) is a major complication after chemoradiotherapy (CRT) for esophageal carcinoma (EC), and causes oral intake impairment leading to deterioration of quality of life even after being cured. Aim of this study was to investigate risk factors of SBCS. Methods: The subjects of this study were patients with stage II/III (T3) EC who received CRT and achieved complete response (CR) between 2000 and 2011. SBCS was determined as disability of passage by diameter-9mm endoscope or procedure to treat symptoms of stricture at the time or after confirmation of CR. Results: Among 197 patients with Stage II/III (T3) treated by CRT, CR was obtained in 87 patients, who were included in this analysis. The median age was 63 years. Fifteen patients (17.2%) were female. The median follow-up time was 7.5 years. The cumulative incidence of SBCS was 15.2% (95%CI 8.5-23.7). Significant risk factors of SBCS were female (hazard ratio (HR) 3.2 (95%CI 1.0-9.7), p ¼ 0.04), requirement of soft/ liquid style diet ), p ¼ 0.004), tumor occupying 3/4 or grater of esophageal perimeter (HR 8.5 (95%CI 1.5-49.1), p ¼ 0.02) and disability of endoscope passage .2), p < 0.001) in univariate analysis. Hypoalbuminemia increased the risk of SBCS (HR 2.6 (95%CI 0.9-7.8), p ¼ 0.08) marginally. As for the factors during CRT, grade 2-4 esophagitis significantly increased the risk of SBCS (HR 5.6 (95%CI 1.4-23.1), p ¼ 0.02). Multivariate analysis showed that hypoalbuminemia (HR 5.6 (95%CI 1.5-21.3), p ¼ 0.01) and disability of endoscope passage (HR 5.9 (95%CI 1.5-22.9), p ¼ 0.01) were the significant risk factors of SBCS. Conclusion: Obstructions and hypoalbuminemia before CRT and severe esophagitis during CRT are considered as risk factors of SBCS. Because SBCS occurred after completion of CRT, prophylactic treatment should be established for esophageal carcinoma patients with risk factors of SBCS. 
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Background: There is no effective chemotherapy for patients with esophageal squamous cell carcinoma (ESCC) refractory or intolerant to 5-fluorouracil (5-FU), platinum, and taxanes. TAS-102 is an oral combination drug of trifluridine and tipiracil hydrochloride. Our preclinical study showed that TAS-102 has antitumor activity against 5-FU resistant esophageal cancer cells. We conducted this study to evaluate the safety and efficacy of TAS-102 in ESCC patients who were refractory or intolerant to standard treatment (UMIN000019268). Methods: Patients with histologically proven advanced or recurrent ESCC, which had been refractory or intolerable to 5-FU, platinum, and taxanes, were eligible. Patients also had to satisfy following criteria: !20 years of age; ECOG performance status 0 or 1; adequate organ functions. TAS-102, 35 mg/m 2 bid, was administered on days 1-5 and 8-12 for the first 2 weeks followed by 2-week rest. The regimen was repeated every 4 weeks until disease progression, serious adverse event, or refusal. Primary endpoint was progression-free survival rate at 3 months (PFS3). With expected PFS3 of 25% to 30% and the null hypothesis of 10% under 80% power and a one-sided significance level of 5%, 35 patients was needed. Results: A total of 42 patients were enrolled. 90% of the patients were male, 95% had distant metastasis, and 98% had target lesion (s). As of data cutoff, 34 events were observed. PFS3 was 15.4% (90% CI: 7.4%, 26.0%), which did not reject the null hypothesis. Median PFS and overall survival were 1.3 months and 4.5 months, respectively. Response rate was 0%, although 24% (10/42) of patients achieved stable disease. There were 3 patients not evaluable for response. Major treatment related adverse events of grade !3 were: neutrophil count decreased (48%), febrile neutropenia (7%), and appetite decreased (5%). No treatment related death was observed. Conclusion: TAS-102 was feasible and showed modest efficacy in patients with refractory ESCC. 
